The role of macrophages in medulloblastoma, the most common malignant pediatric brain tumor, is 3 unclear. Using single-cell RNA sequencing in a mouse model of sonic hedgehog medulloblastoma 4 and analysis of bulk RNA sequencing of human medulloblastoma, we investigated macrophage 5 heterogeneity. Our findings reveal differential recruitment of macrophages with molecular-targeted 6 versus radiation therapy and identify an immunosuppressive monocyte-derived macrophages 7 following radiation treatment of mouse medulloblastoma, uncovering potential strategies for 8 immunomodulation as adjunctive therapy. 9 10 11
Medulloblastoma (MB), one of the most common pediatric brain malignancies, is biologically 24 heterogeneous comprising of four major molecular subgroups: WNT, sonic hedgehog (SHH), group 3, 25 and group 4. Treatment includes surgical resection, chemotherapy, and radiation. Outcome is 26 dependent on clinical-pathological features, patient age, and the presence of metastases. 27
Medulloblastomas are radiosensitive but radiation can lead to severe neurological side-effects which 28 limits its use in young children. The SHH subtype dominates this early age group and is characterized 29 by genetic alterations leading to constitutive activation of the SHH pathway. PTCH1 is a negative 30 regulator of SHH signaling that is mutated in a subset of human SHH-MB patients. Germline deletion 31
of Ptch1 in mice leads to MB with incomplete penetrance, but this increases to 100% penetrance 32 when combined with loss of Tp53 3 . Importantly, Tp53 loss in human SHH-MB is associated with poor 33 prognosis 4 . Hence, Ptch1 +/-:Tp53 -/mice are useful for studying high-risk SHH-MB. Inhibitors of the 34 SHH pathway, such as GDC-0449 (Vismodegib TM ), have shown remarkable efficacy in treating murine SHH-MB and human patients in ongoing clinical trials 5, 6 . However, development of therapeutic 36 resistance to GDC-0449 remains a concern and GDC-0449 is contraindicated in young children 37 because of its negative impact on bone growth 7, 8 . Hence, novel therapies are vitally needed for 38 patients in this high-risk group. 39 40 Among the four different MB subtypes, SHH-MB harbors the most macrophages 9 . The vast majority 41 of studies on macrophages in brain tumors are based on immunohistochemistry, flow cytometry, or 42 transcriptional profiling of bulk tumor tissue, methods that have limited capacity to resolve cellular 43 heterogeneity [9] [10] [11] . Single-cell RNA sequencing (scRNA-Seq) overcomes this limitation and has 44 helped uncover TAM heterogeneity in other solid tumors. In a recent study, scRNA-Seq of human MB 45 provided new insights into tumor heterogeneity but very few macrophages were captured, precluding 46 detailed analyses of TAMs 12 . Furthermore, it remains unclear how these macrophages respond to 47 standard treatment. In this study, we examine TAM composition in MB by performing scRNA-Seq of 48
TAMs in Ptch1 +/-: Tp53 -/mice and corresponding comparisons through the OpenPBTA project to 49 estimate their contributions to bulk RNA-Seq measurements. Importantly, we identify unanticipated 50 differences in the TAM composition in response to radiation and molecular-targeted therapy with 51 GDC-0449, exposing potential strategies for immunomodulation as adjunctive therapy in MB. 52
53
Consistent with previous reports, we find that SHH-MB contains significantly more macrophages than 54 surrounding normal brainstem tissue ( Figure 1a ). To study macrophage heterogeneity, we performed 55 scRNA sequencing (10X genomics) on CD11b+ myeloid cells isolated from the following three types 56 of samples from Ptch1 +/-: Tp53 -/mice: 1) cerebella of 2-week old mice with minimal tumor to capture 57 microglia in normal tissue, 2) peripheral blood of the same mice, 3) and cerebella of 8-week old mice 58 harboring large tumors. Analysis across all three sample types revealed significant alteration in 59 cerebellar macrophage composition in the presence of tumor (Figure 1b ,c). Two large TAM clusters 60 (collectively denoted TAM1 henceforth) aggregated closer to microglia while another three clusters 61 (collectively denoted TAM2 henceforth) aggregated closer to monocytes, suggesting heterogeneous 62 cell-of-origin for macrophages in MB (Figure 1d ). Monocle-based analysis also supported microglia 63 and monocyte origins for TAM1 and TAM2 respectively ( Figure 1e ). 64
Previous studies have shown that only a few markers distinguish microglia from monocyte-derived 66 macrophages in the brain and non-medulloblastoma high grade tumors 1, 10, [13] [14] [15] . Consistent with this, 67 we find only a handful of markers (for example, Siglech, Phgdh, and Pmp22) that distinguished 68 microglia in MB (Supplemental Figure 1a ). Notably, we found expression of certain microglia-69 associated genes (for example, Cd81, Fcrls, Olfml3, Sparc, and Tmem119) in monocyte-derived TAM2 ( Supplementary Figure 1b) , which likely reflects the impact of the brain microenvironment on 71 monocyte-derived macrophages. Likewise, cross-expression of certain markers (for example, Axl, 72 Cst7, Cxcl16, and Ms4a7) in both TAM1 and TAM2 may reflect the impact of tumor-microenvironment 73 on macrophages ( Supplementary Figure 1c ). Certain canonical markers for monocytes such as Ly6c2 74
and Ccr2 were preserved in TAM2 and not present in TAM1 as expected (Supplement Figure1d) . 75
Additional monocyte-associated markers that were preserved in TAM2 includes Plac8, Tgfbi, Iqgap1, 76 Crip1, Vlm, Sirpb1c, S100a6, Plbd1, and Pla2g7. Other markers such as Mgst1 and Chil3 were 77 expressed in monocytes but lost in TAM2 (Supplement Figure1e). These findings will inform ongoing 78 and future efforts to distinguish TAMs and resident brain macrophage subsets. 79
80
We selected Siglech and Clec12a as specific markers of microglia-and monocyte-origins respectively 81 for further validation in MB ( Figure 1f ). Given the vagaries of antibody-based detection, we used 82
RNAscope TM in situ analysis, which confirmed expression of Siglech and Clec12a in the tumor 83 microenvironment (Supplement Figure 2a staining showed mutually exclusive pattern of expression of these markers in tumor ( Figure 1g ). 86
Examining TAM1 and TAM2 using ingenuity pathway analysis (IPA) showed enrichment of pathways 87 associated with antigen presentation, interferon signaling, and activation of interferon regulated 88 factors (IRF) downstream of cytosolic pattern-recognition receptors in TAM2 ( Figure 1h ). 89
90
To examine the relevance of our findings in murine SHH-MB to human patients, we used 91 deconvoluted bulk RNAseq data from 123 patients generated by the collaborative OpenPBTA project. 92 MCP-counter analyses 16 of this dataset showed SHH subtype MB to be significantly enriched 93 (amongst other MB subsets) for monocytes and macrophages, which is consistent with prior 94 published IHC studies 10 (Figure 1i ). Additional analysis using BRETIGEA 17 suggest that all subtypes 95 of MB contain both microglia and monocyte-derived TAMs, albeit at varying proportions ( Figure 1j , 96
There is a great deal of interest in the oncology community to characterize immune responses to 99 traditional forms of treatment such as radiation, chemo, or molecular-targeted therapy. The 100 overarching goal is to identify opportunities to combine these existing treatment modalities with 101 emerging immunotherapeutic approaches. Therefore, we next investigated TAM responses to two 102 distinct treatment modalities; SHH-pathway inhibitor (GDC-0449, twice daily doses of 100mg/kg for 4 103 days) and radiation (3x10Gy). Radiation inducing a much greater macrophage recruitment ( Figure  104  2a ). We performed scRNA-Seq on CD11b+ myeloid cells isolated from tumor-harboring cerebellum of 105 mice treated with each treatment modalities (Figure 2b ,c). Using TAM1-and TAM2-associated 106 markers identified above, we found significantly higher recruitment of monocyte-derived TAMs with 107 radiation when compared to GDC-0449 ( Figure 2d ). We further validated this finding within tumors via 108 RNAscope TM with Siglech and Clec12a probes (Figure 2e ). Hence, molecular-targeted therapy with 109 GDC-0449 and radiation therapy leads to recruitment of ontologically distinct subsets of 110 macrophages. 111 Given the robust recruitment of TAM2 with treatment, we further analyzed this population with and 112 without radiation. Clusters 3 and 5 within TAM2 showed higher expression of prototypical monocyte-113 associated genes Ly6c2 and Ccr2 (Ly6c2/Ccr2 hi ) when compared to clusters 0 and 4 (Ly6c2/Ccr2 lo , 114 Figure 2f ). These latter clusters had higher expression of genes typically associated with microglia 115 (Tmem119, Fcrl2, and Olfml3, Figure 2g ). IPA-based comparison of these all four of these clusters 116 showed adhesion and diapedesis activity as well as higher interferon signature in Ly6c2/Ccr2 hi subset 117 ( Figure 2i ) in comparison to the Ly6c2/Ccr2 lo . Importantly, they also show enrichment of genes in the 118 IL-10 pathway suggesting an immune suppressive phenotype. In contrast, Ly6c2/Ccr2 lo show 119 increased expression of complement and cathepsin genes, suggestive of higher phagocytic activity 120 (Figure 2i ). This may reflect a maturation spectrum where newly generated monocyte-derived 121 macrophages may be more immune-suppressive and gradually turn on microglia associated genes in 122 response to the brain microenvironment as they take on phagocytic functions that are characteristic of 123 mature macrophages.
124 125 To examine the function of monocyte-derived TAM2 in MB, we generated a monocyte-deficient SHH-126 MB model by breeding Ptch1 +/-: Tp53 -/mice with Ccr2 knockout (deficient in circulating monocytes) 127 mice ( Figure 3a ). Henceforth, we refer to Ptch1 +/-: Tp53 -/-Ccr2 -/mice as Ccr2KO and Ptch1 +/-: Tp53 -/-128 mice as Ccr2WT. We performed scRNA-Seq on immune cells isolated from tumor-bearing 129 cerebellum from Ccr2KO and Ccr2WT mice (Figure 3b-d) . Monocyte deficiency was associated with 130 altered myeloid cell recruitment post-radiation, including a significant reduction in Clec12 positive 131 TAMs (Supplement Figure 4) , with a pronounced reduction in Ly6c2/Ccr2 hi clusters (Figure 3e ) in the 132 Ccr2KO. This was also confirmed with flow cytometry (Figure 3f ). Intriguingly, monocyte deficiency 133 increased myeloid clusters 1 and 5, which expressed high levels of neutrophil markers such as 134 S100a9 and Retlng (Figure 3g ). Consistent with this observation, we found significant accumulation of 135 neutrophils (via Ly6G immunohistochemistry) within post-irradiated tumors of Ccr2KO compared to 136 Ccr2WT tumors (Figure 3h ).
137 138
The function of neutrophils in tumor is unclear and may themselves be heterogeneous, but neutrophil 139 infiltration is commonly associated with inflammation, suggesting that the absence of TAM2 may lead 140 to a more inflammatory milieu in radiation treated SHH-MB. Hence, we next asked whether loss of 141 TAM2 with monocyte deficiency might also enhance frequency of intratumoral CD8 T cells. IHC with 142 CD8+ antibody showed significantly higher levels of CD8T cells in post-irradiated tumors in Ccr2KO 143 tumors compared to Ccr2WT (Figure 3i ). These findings suggest that monocyte-derived TAM2 are 144 immunosuppressive. To further assess this, we performed an in vitro T cell proliferation assay in 145 which we co-cultured Ly6C hi cells from irradiated Ccr2WT animals with splenic T cells. Proliferation of 146 CD8T cells were significantly inhibited in the presence of Ly6c hi cells, supporting their 147 immunosuppressive nature (Figure 3j ).
148 149 Our work uncovers phenotypic and ontological heterogeneity within SHH-MB infiltrating TAMs and 150 demonstrates distinct patterns of TAM recruitment with radiation versus molecular-targeted therapy.
151 We find that radiation-induced monocyte derived TAMs are immunosuppressive and their absence 152 engenders a pro-inflammatory tumor microenvironment marked by increased neutrophils and CD8+ T 153 cells. T cell suppression by tumor-infiltrating macrophages is well-known, but the TAM interactions 154 with neutrophils are less well understood. When compared to circulating neutrophils, we found that 155 these tumor-associated neutrophils expressed higher levels of genes associated with communication 156 between innate and adaptive immune system (Supplementary Figure 5 ). In this context, it is not 157 entirely clear whether the increased influx of neutrophils in monocyte-deficient post-irradiated tumors 158 are supportive or inhibitory to the tumor and/or anti-tumor immune responses and warrants further 159 investigation. The increased frequency of CD8+ T cells suggests a potential benefit of combining 160 immune checkpoint blockade (anti-PD1/PDL1) with monocyte depletion (Ccr2-targeting small 161 molecule inhibitors or antibodies) in the setting of radiation therapy in MB. Given the desperate need 162 for new treatment approaches, such evidence-based rational combination therapy may hold promise 163 for brain tumors. from cerebella of eight week old mice (n=2). (d) UMAP of select large clusters that we designate 174 TAM1 for clusters more similar to microglia and TAM2 for those more similar to monocytes. (e) 175 Monocle-based pseudotime analysis of the scRNA-Seq data show TAM1 being more similar to 176 microglia and TAM2 to monocytes. (f) Violin plots displaying expression of genes known to be 177 differentially expressed in ontologically distinct brain macrophages. Microglia-associated Siglech is 178 highly expressed in TAM1 while monocyte-associated Clec12a is highly expressed in in TAM2. 0.026, n=48) and WNT (Wilcoxon p = 0.022, n=20) subtypes, while macrophages with monocyte 242 markers are higher in Group 4 (Wilcoxon p = 1.6e-5, n=116). Material and methods 256 257 Animals
258
Three genetically engineered models purchased from Jackson Laboratory were used: Ptch +/-(stock 259 no. 003081), Tp53 -/-(stock no. 002101), Ccr2 -/-(004999). Ptch1 +/-:Tp53 -/mice were bred and Ccr2 -/-260 genotyping was performed as previously reported 3, 18 . Both males and females of both Ptch1 +/-:Tp53 -/-261 and Ptch1 +/-:Tp53 -/-Ccr2 -/were used for this study. Mice were bred and maintained in specific 262 pathogen free facilities at the University of Pennsylvania. Mice were group-housed (21°C; 12h:12h 263 light:dark cycle) and given ad libitum access to standard rodent diet. All animal procedures were 264 conducted according to National Institutes of Health guidelines and approved by the Institutional 265 Animal Care and Use Committee at the University of Pennsylvania.
266 267 Tumor treatment modalities 268 Mice were treated with SMO inhibitor, GDC-0449 (Chemitek, suspended in 0.5% methylcellulose and 269 0.2% Tween 80) at a dose of 100mg/kg twice a day for 4 days. Brains were resected and analyzed 12 270 hours after the 8 th dose. Radiation treatment was completed on a Small Animal Radiation Research 271 Platform that delivers photon radiation with CT-guided location. Mice that were used for scRNA-Seq 272 received 3 doses of 10Gy radiation on consecutive days. Whole brain were resected for TAM 273 isolation 5 days after the last dose of radiation. Tissues from irradiated mice for all other experiments 274 received 1 dose of 10Gy radiation and tissues were analyzed 3 or 4 days after radiation.
275 276 For radiation treatment, mice were anesthesized with 2% isoflurane in a carrier gas of medical grade 277 air utilizing an induction chamber connected to anesthesia machine (Matrx). Once the mouse reached 278 the desired plane of anesthesia (~2 minutes), the animal was placed on the SARRP's (Xstrahl Life 279 Sciences) irradiation platform with the nose of the mouse in a nosecone where flow of administered 280 isoflurane (maintained at 2%) was remotely controlled using Somnosuite (Kent Scientific) anesthesia 281 system. The mouse tumor was targeted manually with the help of onboard positioning lasers of the 282 SARRP. 10 Gy doses were delivered using 10 mm diameter collimated beam of X-rays with tube 283 potential of 220kVp, 13mA current and dose rate of ~2Gy/min. 284 285 scRNA-Sequencing and analysis 286 Whole cerebellar tissue were mechanically homogenized in RPMI medium. Immune cells were 287 purified using a 70/30 Percoll (Sigma Aldrich, 17-0891-02) gradient spun for 30 minutes at 500G.
288 Cells at the interface were collected and further purified with CD11b+ magnetic microbeads (Miltenyi 289 Biotec, 130-092-636) or CD45 beads (Miltenyi Biotec, 130-052-301 ) through two consecutive LS 290 columns (Miltenyi Biotec, 130-042-401). Peripheral blood was collected in heparinized tubes and 291 spun down to collect cellular components. Red blood cells were lysed (ACK lysing buffer). Remaining 292 lymphocytes were isolated with CD11b+ magnetic beads.
293 294 Next-generation sequencing libraries and sequencing were conducted at the Center for Applied 295 Genomics Core at the Children's Hospital of Philadelphia. Libraries were prepared using the 10x 296 Genomics Chromium Single Cell 3' Reagent kit v2 per manufacturer's instructions. Libraries were 297 uniquely indexed using the Chromium i7 Sample Index Kit, pooled, and sequenced on an Illumina 298 HiSeq sequencer in a paired-end, single indexing run. Sequencing for each library targeted 20,000 299 mean reads per cell. Data was processed using the Cellranger pipeline (10x genomics, v.3.0.2) for 300 demultiplexing and alignment of sequencing reads to the mm10 transcriptome and creation of 301 feature-barcode matrices. Individual single cell RNAseq libraries were aggregated using the 302 cellranger aggr pipeline. Libraries were normalized for sequencing depth across all libraries during 303 aggregation. Secondary analysis on the aggregated feature barcode matrices was performed using 304 the Seurat package (v.3.0) within the R computing environment. Briefly, cells expressing less than 305 200 or more than 4000 genes were excluded from further analysis. Additionally, cells expressing 306 greater than 10% mitochondrial genes were excluded from the dataset. Batch correction was 307 performed using a comprehensive integration algorithm 19 . Log normalization and scaling of features 308 in the dataset was performed prior to principal component dimensionality reduction, clustering, and 309 visualization using UMAP. Generally 15 PCAs were used in each analysis and resolution was set at 310 0.6. Differentially expressed genes and identification of cluster or cell type specific markers were 311 identified using a Wilcoxon rank sum test between each defined group. P-value adjustment was 312 performed using Bonferroni correction based on total number of genes in the aggregated 313 dataset. The monocle library in R was used to determine pseudotime trajectories in separate cell 314 subpopulations. Analysis of differential genes between clusters were performed using Ingenuity 
